Financials in GBp. Standardized financial statements.
A compact view of how CRISM Therapeutics Corporation turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £19,977 | £57,366 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Revenue Growth? | -65.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | £3,196 | £32,000 | £0 | £0 | £5,303 | £4,703 | £4,749 | £6,263 | £1,819 | £0 |
| Gross Profit? | £16,780 | £13,000 | £0 | £0 | -£5,303 | -£4,703 | -£4,749 | -£6,263 | -£1,819 | £0 |
| Gross Margin? | +84.0% | +22.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | £481,851 | £211,088 | £2.22M | £1.30M | £3.27M | £1.55M | £2.01M | £2.12M | £3.43M | £2.68M |
| Operating Income? | -£465,070 | -£216,717 | -£2.22M | -£1.75M | -£3.08M | -£1.56M | -£2.15M | -£1.92M | -£3.77M | -£2.68M |
| EBITDA? | -£452,284 | -£2.26M | -£1.95M | -£1.51M | -£3.08M | -£1.10M | -£2.15M | -£2.12M | -£3.43M | -£2.68M |
| Income Before Tax | -£473,860 | -£257,511 | -£2.60M | -£1.30M | -£2.67M | -£1.83M | -£3.31M | -£1.15M | -£5.77M | -£462,101 |
| Income Tax Expense | £0 | £203,532 | £0 | £240,674 | £0 | -£3.156 | £0 | £0 | £0 | £0 |
| Net Income? | -£485,047 | -£9.65M | -£2.45M | -£1.54M | -£2.08M | -£1.83M | -£3.14M | -£1.20M | -£5.25M | -£462,101 |
| EPS? | £-0.08 | £-0.03 | £-0.28 | £-0.18 | £-0.31 | £-0.40 | £-0.81 | £-0.30 | £-1.53 | £-0.18 |
| Diluted EPS? | £-0.08 | £-0.03 | £-0.28 | £-0.18 | £-0.31 | £-0.40 | £-0.81 | £-0.30 | £-1.53 | £-0.18 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality